Template:PID antibiotics: Difference between revisions
(Convert to AntibioticDose with disease=Pelvic inflammatory disease for SMW linking) |
|||
| Line 4: | Line 4: | ||
==== Outpatient Antibiotic Options ==== | ==== Outpatient Antibiotic Options ==== | ||
* | *{{AntibioticDose|disease=Pelvic inflammatory disease|drug=Ceftriaxone|dose=500mg IM x1 (1g if over 150kg)|context=Outpatient|population=Adult}}<ref>Hayes BD. Trick of the Trade: IV ceftriaxone for gonorrhea. October 9th, 2012 ALiEM. https://www.aliem.com/2012/10/trick-of-trade-iv-ceftriaxone-for/. Accessed October 23, 2018.</ref><ref>Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020 https://www.cdc.gov/mmwr/volumes/69/wr/mm6950a6.htm</ref> x1 + {{AntibioticDose|disease=Pelvic inflammatory disease|drug=Doxycycline|dose=100mg PO BID x 14 days|context=Outpatient|population=Adult}} + {{AntibioticDose|disease=Pelvic inflammatory disease|drug=Metronidazole|dose=500mg PO BID x 14 days|context=Outpatient|population=Adult}} <ref>Ness RB et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002;186:929–37</ref><ref>Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1–187. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1external icon</ref> | ||
**[[Metronidazole]] | **[[Metronidazole]] | ||
***Recommended for empiric treatment of PID by the CDC <ref>Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1–187. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1external icon</ref> | ***Recommended for empiric treatment of PID by the CDC <ref>Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1–187. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1external icon</ref> | ||
***Recommended empirically by European guidelines <ref>Ross J, Guaschino S, Cusini M, Jensen J, 2017 European guideline for the management of pelvic inflammatory disease. Int J STD AIDS. 2018 Feb;29(2):108-114. doi: 10.1177/0956462417744099. Epub 2017 Dec 4.</ref> | ***Recommended empirically by European guidelines <ref>Ross J, Guaschino S, Cusini M, Jensen J, 2017 European guideline for the management of pelvic inflammatory disease. Int J STD AIDS. 2018 Feb;29(2):108-114. doi: 10.1177/0956462417744099. Epub 2017 Dec 4.</ref> | ||
* | *{{AntibioticDose|disease=Pelvic inflammatory disease|drug=Cefoxitin|dose=2g IM x1 with Probenecid 1g PO x1|context=Alt outpatient|population=Adult}}<ref>CDC PID Treatment http://www.cdc.gov/std/treatment/2010/pid.htm</ref> + [[Doxycycline]] 100mg PO BID x 14 days + [[Metronidazole]] | ||
==== Inpatient Antibiotic Options ==== | ==== Inpatient Antibiotic Options ==== | ||
*Recommended<ref>Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1–187. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1external icon</ref>: | *Recommended<ref>Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1–187. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1external icon</ref>: {{AntibioticDose|disease=Pelvic inflammatory disease|drug=Ceftriaxone|dose=1g IV q24hrs|context=Inpatient|population=Adult}} OR {{AntibioticDose|disease=Pelvic inflammatory disease|drug=Cefoxitin|dose=2g IV q6hrs|context=Inpatient|population=Adult}} OR {{AntibioticDose|disease=Pelvic inflammatory disease|drug=Cefotetan|dose=2g IV q12hrs|context=Inpatient|population=Adult}}) + [[Doxycycline]] 100mg PO or IV q12hrs + {{AntibioticDose|disease=Pelvic inflammatory disease|drug=Metronidazole|dose=500mg IV or PO q12hrs|context=Inpatient|population=Adult}} OR | ||
* | *{{AntibioticDose|disease=Pelvic inflammatory disease|drug=Clindamycin|dose=900mg IV q8hrs|context=Inpatient alt|population=Adult}} + {{AntibioticDose|disease=Pelvic inflammatory disease|drug=Gentamicin|dose=2mg/kg loading then 1.5mg/kg q8hrs IV|context=Inpatient alt with Clindamycin|population=Adult}} OR | ||
* | *{{AntibioticDose|disease=Pelvic inflammatory disease|drug=Ampicillin/Sulbactam|dose=3g IV q6hrs|context=Inpatient alt|population=Adult}} + [[Doxycycline]] 100mg IV/PO q12hrs | ||
Revision as of 01:18, 20 March 2026
Antibiotics
- No sexual activity for 2 weeks;
- Treat all partners who had sex with patient during previous 60 days prior to symptom onset
Outpatient Antibiotic Options
- Ceftriaxone 500mg IM x1 (1g if over 150kg)[1][2] x1 + Doxycycline 100mg PO BID x 14 days + Metronidazole 500mg PO BID x 14 days [3][4]
- Cefoxitin 2g IM x1 with Probenecid 1g PO x1[7] + Doxycycline 100mg PO BID x 14 days + Metronidazole
Inpatient Antibiotic Options
- Recommended[8]: Ceftriaxone 1g IV q24hrs OR Cefoxitin 2g IV q6hrs OR Cefotetan 2g IV q12hrs) + Doxycycline 100mg PO or IV q12hrs + Metronidazole 500mg IV or PO q12hrs OR
- Clindamycin 900mg IV q8hrs + Gentamicin 2mg/kg loading then 1.5mg/kg q8hrs IV OR
- Ampicillin/Sulbactam 3g IV q6hrs + Doxycycline 100mg IV/PO q12hrs
- ↑ Hayes BD. Trick of the Trade: IV ceftriaxone for gonorrhea. October 9th, 2012 ALiEM. https://www.aliem.com/2012/10/trick-of-trade-iv-ceftriaxone-for/. Accessed October 23, 2018.
- ↑ Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020 https://www.cdc.gov/mmwr/volumes/69/wr/mm6950a6.htm
- ↑ Ness RB et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002;186:929–37
- ↑ Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1–187. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1external icon
- ↑ Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1–187. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1external icon
- ↑ Ross J, Guaschino S, Cusini M, Jensen J, 2017 European guideline for the management of pelvic inflammatory disease. Int J STD AIDS. 2018 Feb;29(2):108-114. doi: 10.1177/0956462417744099. Epub 2017 Dec 4.
- ↑ CDC PID Treatment http://www.cdc.gov/std/treatment/2010/pid.htm
- ↑ Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1–187. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1external icon
